Analyst Price Target is $31.67
▲ +7.31% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $31.67, with a high forecast of $37.00 and a low forecast of $28.00. The average price target represents a 7.31% upside from the last price of $29.51.
Current Consensus is
Hold
The current consensus among 5 contributing investment analysts is to hold stock in Alkermes. This rating has held steady since January 2023, when it changed from a Buy consensus rating.
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Read More